CRANBURY, N.J., June 28, 2021 /PRNewswire/ -- Palatin
Technologies, Inc. ("Palatin") (NYSE American: PTN) a
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor system, today announced the strengthening of its senior
leadership team with three key executive management appointments:
Michael B. Raizman, M.D. as Chief
Medical Officer; James E. Hattersley
as Senior Vice President of Business Development; and, J.
Don Wang, Ph.D. as Vice President of
"We are proud that we continue to attract the best and brightest
minds who share our passion and approach to bringing impactful
treatments to patients," said Carl
Spana, Ph.D., President and Chief Executive Officer of
Palatin. "We are at a critical stage in the advancement of our
inflammatory and autoimmune programs, and we believe Dr. Raizman,
Mr. Hattersley, and Dr. Wang will significantly aid the Company in
responding to the evolving challenges in the market with agility,
expertise and determination."
Michael B. Raizman, M.D.,
Palatin's newly appointed Chief Medical Officer will report
directly to Dr. Spana. Dr. Raizman will provide leadership and
direction across the entire product pipeline, including clinical
validation, medical and regulatory affairs, and overall clinical,
medical, and regulatory activities. In addition to joining Palatin,
Dr. Raizman is a physician with Ophthalmic Consultants of
Boston and a Diplomate of the
American Board of Ophthalmology, with a specialized knowledge and
expertise in the field of ophthalmology, including development and
clinical evaluation of candidate pharmaceutical products for ocular
diseases. Dr. Raizman received his medical training at Harvard Medical School and the University of Michigan. He completed two
fellowships at the Massachusetts Eye & Ear Infirmary, followed
by three years of research at Harvard Medical
School, funded by a grant from the National Institutes of
Health. Dr. Raizman served on the full-time faculty at Harvard Medical School from 1988-1991. He is a
Fellow of the American Academy of Ophthalmology and is board
certified by the American Board of Ophthalmology. He has served as
an examiner for doctors seeking certification by the American Board
of Ophthalmology. Dr. Raizman is an Associate Professor of
Ophthalmology at Tufts University School of
Medicine, where he has directed the Corneal Fellowship
Program since 1992. He is on the medical staff of the Massachusetts General Hospital, Massachusetts Eye
and Ear, and Tufts Medical Center.
Hattersley, Palatin's newly
appointed Senior Vice President, Business Development,
has more than 25 years of experience in product acquisitions,
corporate alliances and business and corporate development. Mr.
Hattersley will be responsible for all business development
strategies for Palatin's programs. Prior to joining Palatin, Mr.
Hattersley was Senior Vice President for Mission Pharmacal Company
where he was a member of the executive leadership team responsible
for reshaping the company. During his tenure in industry, Mr.
Hattersley identified and executed term sheets for divesting
business unit and pharma product assets; sourced commercial
distribution; co-promoted opportunities for ophthalmic product
additions to sales; and, established alliance management and
increased focus on diligence processes for new product
opportunities. Mr. Hattersley received his M.S. in Biochemistry and
B.A. in Neurobiology from the University of
California, Santa Cruz. He is a member of the Board of
Directors for Temple Therapeutics BV.
J. Don Wang, Ph.D.,
Palatin's newly appointed Vice President of Product Development,
has more than 25 years of experience in the chemical and
pharmaceutical industry conducting research in materials,
formulations, packaging, and manufacturing. Dr. Wang will be
responsible for leading all CMC activities including analytical and
drug substance. Prior to joining Palatin, Dr. Wang was Head of
R&D for American Regent Inc. where he led the corporate R&D
department for injectable product research and development serving
all three internal manufacturing sites throughout the
company. Dr. Wang oversaw teams for formulation, analytical
and process development and directed external R&D
collaborations and projects as well. Dr. Wang received his Ph.D. in
Inorganic Chemistry from Northwestern
University, his M.S. in Chemistry from California State University-Northridge and his B.S.
in Chemistry from Shaanxi Normal University, Xi'an, China.
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com.
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin, are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Palatin intends that such forward-looking statements be subject to
the safe harbors created thereby. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that could cause Palatin's actual results to be materially
different from its historical results or from any results expressed
or implied by such forward-looking statements. Palatin's actual
results may differ materially from those discussed in the
forward-looking statements for reasons including, but not limited
to, sales of Vyleesi in the United
States and elsewhere in the world, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost
required to complete clinical trials and submit applications
for regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
View original content to download
SOURCE Palatin Technologies, Inc.